PharmaFocus Today – Page 16 – media

The first subject has been enrolled in the Phase II clinical trial in China for its innovative drug LY03017, which is used to treat Alzheimer’s disease and psychotic disorders.

Nanfang Finance News, April 15th – Luye Pharma (02186.HK) issued a voluntary announcement stating that its independently developed innovative drug…The first subject has been enrolled in the Phase II clinical trial in China of LY03017 for the treatment of psychotic disorders in Alzheimer’s disease. LY03017 is a new-generation 5-HT2AR inverse agonist and 5-HT2CR antagonist, with target indications including psychotic disorders in Alzheimer’s disease, psychotic disorders in Parkinson’s disease, and negative symptoms of schizophrenia. This Phase II clinical trial is a randomized, double-blind, parallel, placebo-controlled study designed to evaluate the preliminary efficacy and safety of LY03017 in treating hallucinations and delusions associated with Alzheimer’s disease; the drug has previously been approved for clinical trials in the United States. Background: Of the approximately 57 million dementia patients worldwide, 60% to 70% have Alzheimer’s disease, of whom 25% to 50% experience psychotic symptoms. Currently, there are no approved drugs worldwide for this indication. ...
- Source: drugdu
- 87
- April 16, 2026
Its subsidiary’s Phase III clinical trial of “Vitamettrazil” has completed the enrollment of the first patient.

On April 15, China Biopharmaceutical (01177) issued an announcement stating that its wholly-owned subsidiary, Lixin Pharmaceutical Technology (Shanghai) Co., Ltd., has independently developed a Class 1 innovative drug.Vitacoltobayumab (development code: LM-302) is undergoing a Phase III registration clinical trial in combination with a PD-1 monoclonal antibody as first-line treatment for CLDN18.2-positive locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma, and the first patient has been successfully enrolled. LM-302 has been included in the Breakthrough Therapy Program by the China National Medical Products Administration for multiple indications and has received orphan drug designation from the U.S. Food and Drug Administration. https://finance.eastmoney.com/a/202604153705999476.html
- Source: drugdu
- 81
- April 16, 2026
A multi-billion dollar market is fiercely competitive, with Huadong Medicine applying for marketing approval of its megglutinin weight loss product.

On the evening of April 14, Huadong Medicine (000963) issued an announcement stating that its wholly-owned subsidiary, Hangzhou Sino-American Huadong Pharmaceutical Jiangdong Co., Ltd., received an “Acceptance Notice” issued by the National Medical Products Administration (NMPA) for the acceptance of its application for marketing authorization of Smegglutide injection, which is applicable to long-term weight management in adult patients based on diet control and increased physical activity. Previously, Huadong Medicine’s application for marketing authorization of its semaglutide injection for the hypoglycemic indication had been formally accepted by the National Medical Products Administration (NMPA). The acceptance of its application for the weight loss indication signifies that the product is poised to further expand its clinical application scenarios, meeting diverse market demands while gradually unlocking its long-term growth potential in chronic disease management and weight control. Smegglutide injection is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist with 94% sequence homology to human GLP-1. ...
- Source: drugdu
- 112
- April 16, 2026
Another domestically developed AD drug successfully completed Phase III trials.

Recently, Zaijing Pharmaceuticals announced that its independently developed Class 1 new drug, gecacitinib hydrochloride tablets (formerly known as jactinib hydrochloride tablets), has met its primary efficacy endpoint in a multicenter, randomized, double-blind, placebo-controlled phase 3 clinical trial for the treatment of moderate to severe atopic dermatitis in adult patients , demonstrating statistical significance (p<0.0001). This signifies another major breakthrough for Zaijing Pharmaceuticals in the field of autoimmune diseases. Gecacitinib is a novel dual inhibitor of JAK and ACVR1 independently developed by Zaijing Pharmaceuticals , and is classified as a Class 1 new drug. This drug received NMPA approval in May 2025 for the treatment of intermediate- and high-risk myelofibrosis, making it the first domestically produced innovative JAK inhibitor approved for the treatment of myelofibrosis. In addition, the NMPA has accepted the NMPA application for the indication of severe alopecia areata and is currently under review and approval; the three clinical ...
- Source: drugdu
- 97
- April 16, 2026
Henlius’s cetuximab biosimilar HLX05-N received approval in China for clinical trials.

On April 14, 2026, Henlius Biotech (2696.HK) announced that its Investigational New Drug (IND) application for HLX05-N (recombinant anti-EGFR human-mouse chimeric monoclonal antibody injection), a cetuximab biosimilar developed by the company, was approved by the National Medical Products Administration (NMPA) of China for the treatment of metastatic colorectal cancer. Epidermal growth factor receptor (EGFR) belongs to the ErbB family of cell surface erythroleukemia virus oncogene homologs with tyrosine kinase activity. It is a transmembrane glycoprotein widely expressed in normal epithelial cells and tumor tissues such as colorectal cancer and head and neck cancer. EGFR-mediated signaling pathways regulate tumor growth through multiple pathways and play a key regulatory role in the proliferation, differentiation, survival, and metastasis of tumor cells. Therefore, it is considered an important therapeutic target for related tumors. Cetuximab specifically binds to EGFR on the cell surface. On one hand, it competitively inhibits the binding of ligands such as ...
- Source: drugdu
- 97
- April 15, 2026
Huadong Medicine’s application for marketing authorization of megglutide injection for remanufactured fluids has been accepted by the NMPA.

On April 14, 2026, Hangzhou Sino-American Huadong Pharmaceutical Jiangdong Co., Ltd. (hereinafter referred to as “Jiangdong Company”), a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (hereinafter referred to as “the Company”), received the “Acceptance Notice” issued by the National Medical Products Administration (NMPA), in which the marketing authorization application for Smegglutide injection (research code: HDM1702) submitted by Jiangdong Company was accepted. The indication for this application is: This product is suitable for long-term weight management in adult patients based on diet control and increased physical activity, with an initial body mass index (BMI) meeting the following criteria: ≥30kg/m2 ( obese), or ≥27kg/m2 to <30kg/m2 ( overweight) and having at least one weight-related comorbidity, such as hyperglycemia, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. Regarding Smegglutide injection Smegglutide injection is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist with 94% sequence homology to human GLP-1. Clinically, it is mainly used for ...
- Source: drugdu
- 88
- April 15, 2026
Today, Hisun Pharmaceuticals has two pieces of good news.

Recently , Hisun Pharmaceutical surprised the market with two pieces of good news: its net profit for the first quarter of 2026 is expected to increase by 923% to 1095% year-on-year, which is close to twice the net profit of RMB 260 million for the whole of 2025; at the same time, Hisun Pharmaceutical officially announced a licensing cooperation with pharmaceutical giant AbbVie for Nav1.8 inhibitors with a total value of up to US$745 million . >>The Logic Behind the Explosive Growth in Performance Hisun Pharmaceutical expects to achieve a net profit attributable to shareholders of RMB 477 million to RMB 557 million in the first quarter, nearly double its net profit for the entire year of 2025 (RMB 260 million). The core drivers of this surge in performance are twofold: first, the continued strong sales of innovative products such as propofol and cogglitazone, resulting in significant market expansion success; ...
- Source: drugdu
- 81
- April 15, 2026
Established players are increasing their investment in the ASO (App Store Optimization) track.

Alloy Therapeutics recently announced a collaboration and licensing agreement with Biogen, authorizing Biogen to use Alloy’s novel and proprietary AntiClastic™ antisense oligonucleotide (ASO) platform to advance antisense therapies targeting multiple undisclosed targets. Alloy will receive an upfront payment and will be eligible for additional milestone payments and tiered royalties based on any products generated from the collaboration. It is worth noting that Biogen has been deeply involved in the ASO field for many years and has the blockbuster ASO drug Spinraza in hand. This time, choosing to use an external platform to promote the development of the next-generation ASO pipeline is both an endorsement of the Alloy technology platform and an expectation for the next generation of ASO drugs. 01 Biogen’s anxiety In 2025, Boquan’s annual revenue was $9.9 billion, failing to break the $10 billion mark for the third consecutive year, and far from its peak of $14.38 billion ...
- Source: drugdu
- 88
- April 15, 2026
A long-established pharmaceutical company saw its Q1 net profit surge by 985%.

Recently, Wanbangde Pharmaceutical released its performance forecast, showing that it expects to achieve a net profit attributable to the parent company of 165 million yuan in the first quarter of 2026, an increase of 985.40% compared with 15.2018 million yuan in the same period last year ; even more impressive is the net profit excluding non-recurring items, which reached 164 million yuan, while the same period last year was a loss of 7.9053 million yuan, a year-on-year increase of 2174.55% . This performance stands in stark contrast to the company’s 2025 results. According to the company’s previously disclosed preliminary 2025 financial report, Wanbangde’s revenue for the entire year was 1.145 billion yuan, a year-on-year decrease of 20.69%; net profit attributable to the parent company was a loss of 199 million yuan, a significant decrease of 458.54% compared to 55.441 million yuan in the same period of the previous year. The ...
- Source: drugdu
- 83
- April 14, 2026
Domestic Companies Account for 9 Spots, Foreign Companies Only Have 1 Product

Roxadustat capsules from FibroGen (China) . In terms of specific sales figures, Ametinib Mesylate tablets topped the list with sales of 5.53 billion yuan , far ahead of the competition, followed by Vometinib Mesylate tablets with 3.757 billion yuan . The threshold for the top ten has risen to 1.7 billion yuan, with total sales exceeding 26.5 billion yuan. Domestic companies such as Hengrui Medicine, BeiGene, Hansoh Pharmaceutical, Allis, Simcere Pharmaceutical, and Akeso Biopharma are the main players on the list, demonstrating the vigorous vitality of pharmaceutical innovation in China. Note: The products listed in this article are Class 1 innovative drugs approved for marketing in 2016 for chemical drugs and 2020 for traditional Chinese medicine and biological products. Sales data cover the three major terminal markets of domestic hospitals, retail and e-commerce. 01 Domestic innovative drugs account for 9 seats The 2025 list of the top 10 innovative drugs ...
- Source: drugdu
- 96
- April 14, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.